CEACAM20

Summary

CEACAM20 (CEA cell adhesion molecule 20, HGNC:24879) is a protein-coding gene on chromosome 19q13.31, encoding Cell adhesion molecule CEACAM20 (Q6UY09). Together with the tyrosine-protein kinase SYK, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response.

Predicted to enable protein tyrosine kinase binding activity. Predicted to be involved in regulation of immune system process and signal transduction. Predicted to be located in apical plasma membrane and microvillus membrane. Predicted to be active in cell surface and plasma membrane.

Source: NCBI Gene 125931 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 82 total
• GTEx eGene: eQTL in 4 tissues, sQTL in 0 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.05 (unconstrained)
• MANE Select transcript: NM_001102597
• Notable: 82 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24879
Approved symbol	CEACAM20
Name	CEA cell adhesion molecule 20
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	UNQ9366
Ensembl gene	ENSG00000273777
Ensembl biotype	protein_coding
Entrez	125931

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

MANE Select: ENST00000614924

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 5

ENST00000614924, ENST00000611497, ENST00000614577, ENST00000620096, ENST00000621342, ENST00001142114

RefSeq mRNA: 4 — MANE Select: NM_001102597 NM_001102597, NM_001102598, NM_001102599, NM_001102600

CCDS: CCDS74390, CCDS74391, CCDS74392, CCDS74393

Canonical transcript exons

ENST00000614924 — 12 exons

Exon	Start	End
ENSE00003718346	44520474	44520752
ENSE00003718746	44511637	44511672
ENSE00003719973	44512868	44512953
ENSE00003723804	44522634	44522912
ENSE00003726458	44512017	44512078
ENSE00003738495	44525101	44525244
ENSE00003739328	44523986	44524261
ENSE00003740228	44513172	44513289
ENSE00003741427	44511030	44511155
ENSE00003747426	44506159	44506214
ENSE00003752094	44516946	44517224
ENSE00003890488	44529458	44529675

Expression profiles

Bgee: expression breadth broad, 36 present calls, max score 92.71.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1182 / max 146.3176, expressed in 9 samples.

Highest expression (Bgee): duodenum, small intestine, small intestine Peyer’s patch, gall bladder, prostate gland.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CEACAM20 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 4 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

4 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	eqtl	9.9e-06	+0.42	19:44536461:G:A
Adrenal Gland	eqtl	7.1e-03	+1.58	19:44037780:C:T
Lung	eqtl	1.7e-02	-0.25	19:44606802:C:G
Liver	eqtl	2.8e-02	-0.38	19:44738850:G:A

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
181398	0.1061	7
181399	0.0121	3

Top tissues by expression

showing 100 of 116 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	92.71	gold quality
small intestine	UBERON:0002108	78.36	gold quality
small intestine Peyer’s patch	UBERON:0003454	77.92	gold quality
gall bladder	UBERON:0002110	55.78	gold quality
prostate gland	UBERON:0002367	48.10	gold quality
smooth muscle tissue	UBERON:0001135	48.00	gold quality
right lobe of liver	UBERON:0001114	46.94	gold quality
liver	UBERON:0002107	45.47	gold quality
intestine	UBERON:0000160	44.66	gold quality
right adrenal gland cortex	UBERON:0035827	44.57	gold quality
placenta	UBERON:0001987	43.37	gold quality
vermiform appendix	UBERON:0001154	42.11	silver quality
colonic epithelium	UBERON:0000397	41.37	gold quality
right adrenal gland	UBERON:0001233	40.42	gold quality
bone marrow cell	CL:0002092	40.27	gold quality
stromal cell of endometrium	CL:0002255	39.49	gold quality
lower esophagus mucosa	UBERON:0035834	38.72	gold quality
rectum	UBERON:0001052	38.71	silver quality
left testis	UBERON:0004533	38.54	gold quality
right testis	UBERON:0004534	38.39	gold quality
testis	UBERON:0000473	38.35	gold quality
left adrenal gland cortex	UBERON:0035825	37.67	gold quality
bone marrow	UBERON:0002371	37.48	gold quality
granulocyte	CL:0000094	37.45	gold quality
muscle tissue	UBERON:0002385	37.38	gold quality
left adrenal gland	UBERON:0001234	37.35	silver quality
adrenal gland	UBERON:0002369	36.99	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
apex of heart	UBERON:0002098	36.25	gold quality
tonsil	UBERON:0002372	36.07	gold quality
sural nerve	UBERON:0015488	35.99	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
skeletal muscle tissue	UBERON:0001134	34.60	gold quality
mucosa of stomach	UBERON:0001199	34.48	gold quality
urinary bladder	UBERON:0001255	33.58	silver quality
transverse colon	UBERON:0001157	33.45	gold quality
leukocyte	CL:0000738	32.59	gold quality
monocyte	CL:0000576	32.44	gold quality
cortex of kidney	UBERON:0001225	32.22	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
colon	UBERON:0001155	32.12	gold quality
prefrontal cortex	UBERON:0000451	30.49	gold quality
lymph node	UBERON:0000029	30.29	gold quality
adrenal tissue	UBERON:0018303	29.97	gold quality
right uterine tube	UBERON:0001302	29.93	gold quality
fallopian tube	UBERON:0003889	29.89	silver quality
endometrium	UBERON:0001295	29.63	gold quality
myometrium	UBERON:0001296	29.39	gold quality
uterine cervix	UBERON:0000002	29.05	gold quality
multicellular organism	UBERON:0000468	28.76	gold quality
fundus of stomach	UBERON:0001160	28.73	gold quality
endocervix	UBERON:0000458	28.54	gold quality
right hemisphere of cerebellum	UBERON:0014890	28.19	gold quality
kidney	UBERON:0002113	28.07	gold quality
islet of Langerhans	UBERON:0000006	28.03	gold quality
pituitary gland	UBERON:0000007	27.79	silver quality
cerebellar hemisphere	UBERON:0002245	27.51	gold quality
cerebellar cortex	UBERON:0002129	27.44	gold quality
pancreas	UBERON:0001264	27.43	gold quality
right atrium auricular region	UBERON:0006631	27.41	gold quality
cerebellum	UBERON:0002037	27.40	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	27.39	gold quality
ectocervix	UBERON:0012249	27.25	gold quality
calcaneal tendon	UBERON:0003701	26.89	gold quality
frontal cortex	UBERON:0001870	26.75	gold quality
adenohypophysis	UBERON:0002196	26.57	gold quality
tibial nerve	UBERON:0001323	26.56	gold quality
body of pancreas	UBERON:0001150	26.15	gold quality
right lung	UBERON:0002167	26.07	gold quality
body of uterus	UBERON:0009853	26.04	gold quality
muscle layer of sigmoid colon	UBERON:0035805	25.81	silver quality
skin of leg	UBERON:0001511	25.49	gold quality
tibial artery	UBERON:0007610	25.48	gold quality
popliteal artery	UBERON:0002250	25.43	gold quality
Ammon’s horn	UBERON:0001954	25.30	gold quality
cerebral cortex	UBERON:0000956	25.26	gold quality
esophagus	UBERON:0001043	25.18	gold quality
esophagus mucosa	UBERON:0002469	25.08	gold quality
lower esophagus	UBERON:0013473	25.01	gold quality
lower esophagus muscularis layer	UBERON:0035833	25.00	gold quality
zone of skin	UBERON:0000014	24.96	gold quality
spleen	UBERON:0002106	24.92	gold quality
primary visual cortex	UBERON:0002436	24.61	gold quality
descending thoracic aorta	UBERON:0002345	24.58	gold quality
metanephros cortex	UBERON:0010533	24.56	gold quality
left uterine tube	UBERON:0001303	24.43	gold quality
superior frontal gyrus	UBERON:0002661	24.08	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	24.06	gold quality
ascending aorta	UBERON:0001496	24.05	gold quality
thoracic aorta	UBERON:0001515	24.04	gold quality
thyroid gland	UBERON:0002046	24.01	gold quality
right ovary	UBERON:0002118	23.98	gold quality
left lobe of thyroid gland	UBERON:0001120	23.79	gold quality
skin of abdomen	UBERON:0001416	23.74	gold quality
substantia nigra	UBERON:0002038	23.58	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	23.58	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	23.50	gold quality
temporal lobe	UBERON:0001871	23.23	gold quality
ovary	UBERON:0000992	23.17	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.09
E-ENAD-17	no	45.20

HPA expression

RNA tissue specificity: Tissue enriched

37 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Small intestine	tissue	35.6
Duodenum	tissue	35.2
Prostate	tissue	7.9
Cerebellum	tissue	1.5
Olfactory bulb	tissue	1.3
Cerebral cortex	tissue	1.1
Retrosplenial and cingulate cortex	tissue	1.1
Retrosplenial cortex	tissue	1.1
Occipital cortex	tissue	1.1
Insular cortex	tissue	1.1
Prefrontal cortex	tissue	1.0
Motor cortex	tissue	1.0
Basal ganglia	tissue	1.0
Amygdala	tissue	1.0
Corpus callosum	tissue	1.0
Hippocampal formation	tissue	1.0
Entorhinal cortex	tissue	1.0
Somatosensory cortex	tissue	1.0
Temporal cortex	tissue	1.0
Ventral forebrain	tissue	0.9
Septum	tissue	0.9
Putamen	tissue	0.8
Periaqueductal gray	tissue	0.8
Medulla oblongata	tissue	0.7
Hypothalamus	tissue	0.7
Superior colliculi	tissue	0.7
Substantia nigra	tissue	0.7
Gallbladder	tissue	0.7
Spinal cord	tissue	0.7
Pons	tissue	0.6
Midbrain	tissue	0.6
Thalamus	tissue	0.6
Testis	tissue	0.4
Smooth muscle	tissue	0.3
Placenta	tissue	0.1
Liver	tissue	0.1
Tonsil	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 9; highest nTPM — Subiculum (1.0), White matter (1.0), Dorsal hippocampus (0.9), Ventral hippocampus (0.9), Dorsal spinal cord (0.7).

Regulation

Is transcription factor: no

Functional genomics

gnomAD constraint: pLI 1.97e-14, LOEUF 1.05, missense Z 0.991 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000614924 — one region, missense o/e 0.93.

Literature-anchored findings (GeneRIF, showing 2)

• conclude that CEACAM20 and CEACAM1 not only mark the lumina of adult prostate tissue but also play a critical role in the vitro generation of prostate organoids (PMID:23358633)
• tyrosine phosphorylation of CEACAM20 likely promotes phagocytic activity (PMID:28659570)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkeyp-97a10.3	ENSDARG00000104656
danio_rerio	si:dkey-11o1.7	ENSDARG00000105324
mus_musculus	Ceacam20	ENSMUSG00000070777
rattus_norvegicus	Ceacam20	ENSRNOG00000019260

Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137)

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ZNF180	protein-coding	7733
ZNF229	protein-coding	7772
MIR4531	ncRNA	100616355
IGSF23	protein-coding	147710
CEACAM19	protein-coding	56971
PVR	protein-coding	5817
ZNF285	protein-coding	26974

Protein

Protein identifiers

Cell adhesion molecule CEACAM20 — Q6UY09 (reviewed: Q6UY09)

Alternative names: Carcinoembryonic antigen-related cell adhesion molecule 20

All UniProt accessions (1): Q6UY09

UniProt curated annotations — full annotation on UniProt →

Function. Together with the tyrosine-protein kinase SYK, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response.

Subunit / interactions. Interacts (via extracellular domain) with PTPRH (via extracellular domain); the interaction dephosphorylates CEACAM20. Interacts (phosphorylated form) with SYK (via SH2 domains); the interaction further enhances CEACAM20 phosphorylation.

Subcellular location. Cell projection. Microvillus membrane. Apical cell membrane.

Post-translational modifications. Phosphorylated on tyrosine residues by SYK, SRC and FYN in vitro.

Similarity. Belongs to the immunoglobulin superfamily. CEA family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q6UY09-1	1	yes
Q6UY09-2	2
Q6UY09-3	3
Q6UY09-4	4
Q6UY09-5	5

RefSeq proteins (4): NP_001096067, NP_001096068, NP_001096069, NP_001096070 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR052598	IgSF_CEA-related	Family

Pfam: PF13927

UniProt features (37 total): glycosylation site 7, sequence variant 7, domain 4, disulfide bond 3, splice variant 3, region of interest 2, compositionally biased region 2, modified residue 2, topological domain 2, sequence conflict 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UY09-F1	73.87	0.52

Human Protein Atlas

Protein class: Predicted membrane proteins, UniProt - Evidence at transcript level

Protein evidence: Evidence at protein level

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
Phosphotyrosine	578, 589

Disulfide bonds (3)

Type	Positions
Disulfide bond	90–138, 276–324, 375–416

Glycosylation sites (7)

Type	Positions
N-linked (glcnac…) asparagine	96, 105, 280, 306, 317, 368, 415

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 40 (showing top): GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, SHEPARD_BMYB_MORPHOLINO_DN, GOBP_CYTOKINE_PRODUCTION, GOCC_APICAL_PLASMA_MEMBRANE, AACTTT_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOCC_CELL_PROJECTION_MEMBRANE, GOCC_APICAL_PART_OF_CELL, GOCC_MICROVILLUS, GOCC_MICROVILLUS_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOCC_ACTIN_BASED_CELL_PROJECTION, GOBP_RESPONSE_TO_BACTERIUM, GOMF_KINASE_BINDING

GO Biological Process (5): positive regulation of cytokine production (GO:0001819), immune system process (GO:0002376), regulation of immune system process (GO:0002682), signal transduction (GO:0007165), response to bacterium (GO:0009617)

GO Molecular Function (1): protein tyrosine kinase binding (GO:1990782)

GO Cellular Component (4): plasma membrane (GO:0005886), cell surface (GO:0009986), apical plasma membrane (GO:0016324), microvillus membrane (GO:0031528)

GO top-level categories

21 GO namespaces:

Category	Terms
cytokine production	1
regulation of cytokine production	1
positive regulation of gene expression	1
positive regulation of multicellular organismal process	1
biological_process	1
immune system process	1
regulation of biological process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
response to other organism	1
protein kinase binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1
apical part of cell	1
plasma membrane region	1
microvillus	1
cell projection membrane	1

Protein interactions and networks

STRING

showing 15 of 232 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEACAM20	CEACAM19	Q7Z692	746
CEACAM20	CEACAM4	O75871	610
CEACAM20	CEACAM3	P40198	495
CEACAM20	PRAMEF19	Q5SWL8	419
CEACAM20	ZNF23	P17027	400
CEACAM20	A0A087WTH5	A0A087WTH5	359
CEACAM20	OR10G2	Q8NGC3	345
CEACAM20	CEACAM18	A8MTB9	337
CEACAM20	SMIM11	P58511	315
CEACAM20	SPDYE3	A6NKU9	314
CEACAM20	LHFPL1	Q86WI0	308
CEACAM20	TRERF1	Q96PN7	295
CEACAM20	PTPRH	Q9HD43	273
CEACAM20	RGPD1	P0C839	270
CEACAM20	CEACAM21	Q3KPI0	262

Disease & clinical

Genetic variants

Variant evidence for CEACAM20: 82 ClinVar records (0 pathogenic / likely pathogenic); 5 GWAS associations.

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	4
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 34 predictions of 897):

Position(s)	Effect	Δscore	Sites
19:44511594	donor_gain	1.0000
19:44512955	acceptor_loss	1.0000
19:44511028–44511029	donor_loss	0.9900	5
19:44511156–44511157	acceptor_loss	0.9900	4
19:44512015–44512016	donor_loss	0.9900	5
19:44512079–44512080	acceptor_loss	0.9900	4
19:44512866–44512867	donor_loss	0.9900	5
19:44512954–44512955	acceptor_loss	0.9900	2
19:44513290–44513291	acceptor_loss	0.9900	6
19:44524262	acceptor_gain	0.9900

AlphaMissense

437 missense substitutions predicted likely pathogenic (of 3,866 scored), across 152 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D132	8	0.885	0.948
W287	7	0.968	0.995
C324	7	0.963	0.981
C276	7	0.961	0.981
C416	7	0.960	0.986
W387	7	0.956	0.994
C375	7	0.950	0.982
W101	7	0.928	0.987
C138	7	0.917	0.976
C90	7	0.889	0.945
W201	7	0.867	0.968
C230	7	0.858	0.941
N420	7	0.852	0.972
D318	7	0.807	0.892
N234	7	0.781	0.949
S335	6	0.880	0.966
P346	6	0.875	0.961
G345	6	0.865	0.963
S149	6	0.822	0.948
V156	6	0.800	0.923

HPA cancer prognostics

RNA cancer specificity: Cancer enriched (Prostate Adenocarcinoma)

Disease associations

OMIM: gene `` | disease phenotypes:

GWAS associations

5 associations:

Study	Trait	p-value
GCST007320_18	Alzheimer’s disease or family history of Alzheimer’s disease	1e-12
GCST005952_8	Body mass index (age>50)	9e-12
GCST005950_15	Body mass index x sex x age interaction (4df test)	2e-10
GCST005954_4	Body mass index x age interaction	2e-7
GCST005951_66	Body mass index	1e-6

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0009268	family history of Alzheimer’s disease

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
methyleugenol	decreases expression	1
bisphenol A	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Thiram	increases expression	1
Urethane	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

12 trials:

NCT	Phase	Status	Title
NCT03414970	Phase 3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	Phase 2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	Phase 2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	Phase 1/2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	Phase 1/2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	Early Phase 1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	Early Phase 1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT07628634	Early Phase 1	RECRUITING	Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
NCT01208974	Not specified	COMPLETED	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery